Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jun;21(6):336-341.
doi: 10.1111/1751-2980.12913.

Serum biomarkers of fibrostenotic Crohn's disease: Where are we now?

Jin Shen He  1 , Jin Yu Tan  1 , Xiao Zhi Li  1 , Rui Feng  1 , Shan Shan Xiong  1 , Si Nan Lin  1 , Yun Qiu  1 , Ren Mao  1
Affiliations
Review

Serum biomarkers of fibrostenotic Crohn's disease: Where are we now?

Jin Shen He et al. J Dig Dis. 2020 Jun.

Abstract

Intestinal fibrosis and subsequent stricture formation are major clinical challenges in inflammatory bowel disease, resulting in an increased rate of operation and poor prognosis compared with those without. With the changing perception that intestinal fibrosis is irreversible to the point of view that it is reversible in recent years, various candidate serum biomarkers have been studied over the past decades, which may stratify patients based on their risks of developing stenosis and enable the detection of early stages of fibrosis. However, reliable and accurate biomarkers are still unavailable due to conflicting results and the lack of high-quality evidence. In this review we summarized the serum biomarkers that have been proposed for intestinal fibrosis in recent years, which includes gene polymorphisms or variants, epigenetic markers, extracellular matrix components, growth factors, and antibodies, aiming to provide clues for future research.

Keywords: Crohn's disease; biomarker; fibrostenotic Crohn's disease; inflammatory bowel diseases.

PubMed Disclaimer

References

REFERENCES

    1. Lawrance IC, Rogler G, Bamias G, et al. Cellular and molecular mediators of intestinal fibrosis. J Crohns Colitis. 2015;11(12):1491-1503.
    1. Burke JP, Mulsow JJ, O'Keane C, Docherty NG, Watson RWG, O'Connell PR. Fibrogenesis in Crohn's disease. Am J Gastroenterol. 2007;102(2):439-448.
    1. de Bruyn JR, Meijer SL, Wildenberg ME, Bemelman WA, van den Brink GR, D'Haens GR. Development of fibrosis in acute and longstanding ulcerative colitis. J Crohns Colitis. 2015;9(11):966-972.
    1. Di Sabatino A, Jackson CL, Pickard KM, et al. Transforming growth factor β signalling and matrix metalloproteinases in the mucosa overlying Crohn's disease strictures. Gut. 2009;58(6):777-789.
    1. Liu X. Inflammatory cytokines augments TGF-β1-induced epithelial-mesenchymal transition in A549 cells by up-regulating TβR-I. Cell Motil Cytoskeleton. 2008;65(12):935-944.

LinkOut - more resources